Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Mokhtari, Reza B ^a,b   Kumar, Sushil ^b   Islam, Syed S ^b   Yazdanpanah, Mehrdad ^b   Adeli, Khosrow ^a,b   Cutz, Ernest ^a,b,c   Yeger, Herman ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acetazolamide; Bronchial carcinoids; Carbonic anhydrase; Pulmonary neuroendocrine tumor; Serotonin; Sulforaphane

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CHROMOGRANIN A; HISTONE H3; KI 67 ANTIGEN; OXYGENASE; SEROTONIN; SULFORAPHANE; TRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS CARCINOID; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN H 720; CELL STRAIN H 727; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FETUS; GROWTH INHIBITION; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; SECRETORY VESICLE; SUBCUTANEOUS TISSUE TUMOR; TREATMENT DURATION; TUMOR INVASION; TUMOR XENOGRAFT; ULTRASTRUCTURE;

ACETAZOLAMIDE; ANIMALS; ANTINEOPLASTIC AGENTS; BRONCHIAL NEOPLASMS; CARBONIC ANHYDRASE INHIBITORS; CARCINOID TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; ISOTHIOCYANATES; MICE; SEROTONIN; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884588943     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-378     Document Type: Article

References (61)

1. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008, 113:2655-2664. 10.1002/cncr.23883, 18853416.
2. Pusceddu S, Catena L, Valente M, Buzzoni R, Formisano B, Del Vecchio M, Ducceschi M, Tavecchio L, Fabbri A, Bajetta E. Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis. J Thor Disease 2010, 2:16-20.
3. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist 2008, 13:1255-1269. 10.1634/theoncologist.2008-0207, 2901509, 19091780.
4. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005, 10:123-131. 10.1634/theoncologist.10-2-123, 15709214.
5. Walther DJ, Peter JU, Bader M. 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors. Cancer 2002, 94:3135-3140. 10.1002/cncr.10592, 12115345.
6. Neri D, Supuran CT. Interfering with pH regulation in tumors as a therapeutic strategy. Nat Rev Drug Discov 2011, 10:767-777. 10.1038/nrd3554, 21921921.
7. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004, 64:6160-6165. 10.1158/0008-5472.CAN-03-2224, 15342400.
8. Pastorekova S, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 2007, 7:865-878. 10.2174/156802607780636708, 17504131.
9. Arvidsson Y, Bergstrom A, Arvidsson L, Kristansson E, Ahlman H, Nilsson O. Hypoxia stimulates CXCR4 signaling in ileal carcinoids. Endocr Relat Cancer 2010, 17:303-316. 10.1677/ERC-09-0085, 20071457.
10. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008, 7:168-181. 10.1038/nrd2467, 18167490.
11. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One 2010, 5:1-9.
12. Cianchi F, Vinci CM, Supuran CT, Peruzzi B, De Giuli P, Fasolis G, Perigli G, Pastorekova S, Papucci L, Pini A, Masini E, Puccetti L. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 2010, 334:710-719. 10.1124/jpet.110.167270, 20519553.
13. Ishizuka J, Beauchamp RD, Townsend CMJR, Greeley GHJR, Thompson JC. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 1992, 150:1-7. 10.1002/jcp.1041500102, 1309821.
14. Drozdov I, Kidd M, Gustafsson BI, Svejda B, Joseph R, Pfragner R, Modlin IM. Auto-regulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer 2009, 115:4934-4945. 10.1002/cncr.24533, 2767432, 19634160.
15. Fu XW, Nurse CA, Wong V, Cutz E. Hypoxia-induced secretion of serotonin from intact pulmonary neuroepithelial bodies in neonatal rabbit. J Physiol 2002, 539:503-510. 10.1113/jphysiol.2001.013071, 2290169, 11882682.
16. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004, 3:164-167.
17. Alvarez LJ, Turner HC, Zamudio AC, Candia OA. Serotonin-elicited inhibition of Cl- secretion in the rabbit conjunctival epithelium. Am J Physiol Cell Physiol 2001, 280:581-592.
18. Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS, Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010, 16:2580-2590. 10.1158/1078-0432.CCR-09-2937, 2862133, 20388854.
19. Chaudhuri D, Orsulic S, Ashok BT. Antiproliferative activity of sulforaphane in akt-overexpressing ovarian cancer cells. Mol Cancer Ther 2007, 6:334-345. 10.1158/1535-7163.MCT-06-0404, 2584019, 17237292.
20. Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res 2001, 61:6656-6659.
21. Pitt SC, Chen H, Kunnimalaiyaan M. Phosphatidylinositol 3-kinase-akt signaling in pulmonary carcinoid cells. J Am Coll Surg 2009, 209:82-88. 10.1016/j.jamcollsurg.2009.03.006, 2910111, 19651067.
22. Parnaud G, Li P, Cassar G, Rouimi P, Tulliez J, Combaret L, Gamet-Payrastre L. Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr Cancer 2004, 48:198-206. 10.1207/s15327914nc4802_10, 15231455.
23. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010, 5:1-13. 10.1186/1750-2187-5-1, 2848036, 20167101.
24. Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, Okayasu I. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004, 17:1259-1267. 10.1038/modpathol.3800176, 15154011.
25. Dashwood RH, Ho E. Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates. Nutrition Review 2008, 66:36-38.
26. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol 2009, 16:481-486. 10.1245/s10434-008-0194-6, 2740795, 19030935.
27. Wang XF, Wu DM, Li BX, Lu YJ, Yang BF. Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. Phytother Res 2009, 23:303-307. 10.1002/ptr.2618, 18844240.
28. Jiang H, Shang X, Wu H, Huang G, Wang Y, Al-Holou S, Gautam SC, Chopp M. Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res 2009, 35:152-161. 2821708, 19685289.
29. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov AV, Herr I. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010, 70:5004-5013. 10.1158/0008-5472.CAN-10-0066, 20530687.
30. Lin LC, Yeh CT, Kuo CC, Lee CM, Yen GC, Wang LS, Wu CH, Yang WC, Wu AT. Sulforaphane potentiates the efficacy of Imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. J Agric Food Chem 2012, 60:7031-7039. 10.1021/jf301981n, 22708678.
31. Mastrangelo L, Cassidy A, Mulholland F, Wang W, Bao Y. Serotonin receptors, novel targets of sulforaphane identified by proteomic analysis in Caco-2 Cells. Cancer Res 2008, 68:5487-5491. 10.1158/0008-5472.CAN-07-6171, 18593952.
32. Yan Z, Caldwell GW, Zhao B, Reitz AB. A high-throughput monoamine oxidase inhibition assay using liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 2004, 18:834-840. 10.1002/rcm.1415, 15095350.
33. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective anti depressive medications. Chem Biol 2006, 13:563-567. 10.1016/j.chembiol.2006.05.004, 16793513.
34. Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem cell 2008, 26:1818-1830.
35. Idikio HA. Spindle checkpoint protein hMad2 and histone H3 phosphoserine 10 mitosis marker in pediatric solid tumors. Anticancer Res 2006, 26:4687-4694.
36. Erikkson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?. Curr Opin Oncol 2010, 22:381-386. 10.1097/CCO.0b013e32833adee2, 20473165.
37. Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012, 130:491-496. 10.1002/ijc.26396, 21898386.
38. Dong M, Yao JC. mTOR inhibition, a potential novel approach for bronchial carcinoids. Endoc-Relat Cancer 2011, 18:115-118.
39. Cutz E, Yeger H, Pan J, Ito T. Pulmonary neuroendocrine cell system in health and disease. Curr Resp Med Rev 2008, 27:174-186.
40. Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors analysis of the phase 3, randomized, placebo-controlled radiant-2 study. Chest 2013, 143(4):955-962. 10.1378/chest.12-1108, 23187897.
41. Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, Sly WS. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000, 97:2220-2224. 10.1073/pnas.040554897, 15781, 10688890.
42. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Buchler MW, Salinkov AV, Herr I. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 2011, 19:188-195. 10.1038/mt.2010.216, 3017446, 20940707.
43. Li X, Xiang Y, Ma B, Qi X. Effects of acetazolamide combined with or without NaHCO3 on suppressing neoplasm growth, metastasis and aquaporin-1(AQP1) protein expression. Int J Mol Sci 2007, 1:229-240.
44. Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 2010, 17:977-987. 10.1677/ERC-10-0157, 20817788.
45. Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, We{ogonek}sierska-Ga{ogonek}dek J, Haitel A, Filipits M, Berger W, Schmid K. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology 2012, 96:228-237. 10.1159/000337257, 22378048.
46. Jakubíková J, Sedlák J, Mithen R, Bao Y. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 2005, 69:1543-1552. 10.1016/j.bcp.2005.03.015, 15896333.
47. Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD. Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS One 2012, 7:e51251. 10.1371/journal.pone.0051251, 3521002, 23251470.
48. Shafee N, Kaluz S, Ru N, Stanbridge EJ. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Letter 2009, 282:109-115.
49. Kaluz S, Kaluzová M, Stanbridge EJ. The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. J Cell Biochem 2006, 97:207-216. 10.1002/jcb.20633, 16270297.
50. Matsumoto S, Tanimoto T, Yoshida S, Ikeda M, Takeda M, Saiki C, Shimazu Y, Aoba T, Nasu M, Suzuki K. Effects of acetazolamide and 4-Aminopyridine on CO2-induced slowly adapting pulmonary stretch receptor inhibition in rats. Chem Senses 2004, 29:351-361. 10.1093/chemse/bjh038, 15150148.
51. Shankar S, Ganapathy S, Srivastava RK. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 2008, 14:6855-6866. 10.1158/1078-0432.CCR-08-0903, 18980980.
52. Sawaoka H, Kawano S, Tsuji S, Tsuji M, Gunawan ES, Takei Y, Nagano K, Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998, 274:1061-1067.
53. Jafarau G, Xie Y, Kullyev A, Liang B, Sze YJ. Regulation of extrasynaptic 5-HT by SERT function in 5-HT-absorbing neurons underscores adaptation behavior in C. elegans. J Neurosci 2011, 31:8948-8957. 10.1523/JNEUROSCI.1692-11.2011, 3153855, 21677178.
54. Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 2011, 136:252-259. 10.1309/AJCPDXFOPXGEF0RP, 21757598.
55. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 2010, 5:453-4599. 10.1097/JTO.0b013e3181ca063b, 20104194.
56. Ravina E. The Evaluation of Drug Discovery from Traditional Medicines to Modern drugs. In Edited by Ravina E. Weinheim 2011, Germany: WILEY-VCH Verlag & Co. KGaA. Boschstr Press.
57. Jee HG, Lee KE, Kim JB, Shin HK, Youn YK. Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro. Phytother Res 2011, 25:1623-1628. 10.1002/ptr.3397, 21413088.
58. Bryant CS, Kumar S, Chamala S, Shah J, Pal J, Haider M, Seward S, Qazi AM, Morris R, Semaan A, Shammas MA, Steffes C, Potti RB, Prasad M, Weaver DW, Batchu RB. Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol Cancer 2010, 9:10-16. 10.1186/1476-4598-9-10, 2818692, 20085660.
59. Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil 2011, 23:193-200. 10.1111/j.1365-2982.2010.01643.x, 3076306, 21159063.
60. Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, Suestsugi M, Watanabe Y. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 2010, 23:263-270.
61. Brian Cornblatt S, Lingxiang Y, Albena T, Kostova D, Melanie E, Fahey JW, Singh NK, Min-Shue Chen A, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 2007, 28:1485-1490. 10.1093/carcin/bgm049, 17347138.